Takeda Highlights Rare Neurological Disorder Programs In Wave 1

Company Already Has Pivoted Away From Larger Psychiatric Indications

 
• By Joseph Haas
  
Takeda Tokyo HQ
Takeda gave investors another update on its Wave 1 R&D effort
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Neurological

More from Therapeutic Category